Roth Positive on Pharmacyclics (PCYC) Following CHMP Recommendation of Imbruvica
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $183 target price on Pharmacyclics (Nasdaq: PCYC) following news that the pharma's Imbruvica ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
